MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.31
+0.21
+1.56%
After Hours: 13.31 0 0.00% 17:10 04/02 EDT
OPEN
12.67
PREV CLOSE
13.11
HIGH
13.40
LOW
12.44
VOLUME
610.07K
TURNOVER
--
52 WEEK HIGH
48.40
52 WEEK LOW
9.24
MARKET CAP
992.26M
P/E (TTM)
-37.4824
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MYGN stock price target is 20.29 with a high estimate of 36.00 and a low estimate of 10.00.

EPS

MYGN News

More
  • B of A Securities Reiterates Underperform on Myriad Genetics, Lowers Price Target to $13
  • Benzinga · 13h ago
  • Myriad Genetics seeks expanded use of BRACAnalysis in Japan
  • Seeking Alpha - Article · 3d ago
  • Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
  • GlobeNewswire · 3d ago
  • A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
  • Simply Wall St. · 03/23 12:13

Industry

Medical Equipment, Supplies & Distribution
+2.77%
Healthcare Equipment & Supplies
+3.32%

Hot Stocks

Symbol
Price
%Change

About MYGN

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
More

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.